Payment overview · 2025
General Payments
$538.23
19 reported records · 8 companies
Healthcare provider profile · identity verified
John Lumir Bender, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FORT COLLINS, CO · NPI 1609864065
Verified facts
What the public records show
CMS Open Payments records show John Lumir Bender, M.D. received $538.23 in general payments during 2025 across 19 reported records.
ABBVIE INC. accounted for 38.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $205.88 | 38.2% | 8 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $128.36 | 23.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $95.75 | 17.8% | 4 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $30.64 | 5.7% | 1 | 2025 |
| Electromed, Inc. | Unresolved — no canonical attribution shown | $20.80 | 3.9% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.58 | 3.6% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $18.70 | 3.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.52 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $538.23 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $134.06 | 5 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $128.36 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $95.75 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $71.82 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $48.29 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $30.64 | 1 | 2025 |
Source payment records
|
|||||
| SMARTVEST Normalized: smartvest |
Device | Electromed, Inc. | $20.80 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $19.58 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.58 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 279 | 89 |
| Losartan Potassium | Losartan Potassium | 245 | 84 |
| Atorvastatin Calcium | Atorvastatin Calcium | 240 | 87 |
| Amlodipine Besylate | Amlodipine Besylate | 175 | 58 |
| Omeprazole | Omeprazole | 153 | 54 |
| Metformin Hcl | Metformin Hcl | 148 | 47 |
| Lisinopril | Lisinopril | 131 | 53 |
| Trazodone Hcl | Trazodone Hcl | 105 | 33 |
| Oxycodone Hcl | Oxycodone Hcl | 101 | 13 |
| Gabapentin | Gabapentin | 81 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 75 | 35 |
| Sertraline Hcl | Sertraline Hcl | 73 | 21 |
| Carvedilol | Carvedilol | 69 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 69 | 15 |
| Bupropion Xl | Bupropion Hcl | 65 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 18 |
| Furosemide | Furosemide | 64 | 24 |
| Simvastatin | Simvastatin | 61 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 56 | 13 |
| Topiramate | Topiramate | 54 | 18 |
| Metformin Hcl Er | Metformin Hcl | 53 | 19 |
| Allopurinol | Allopurinol | 50 | 15 |
| Xarelto | Rivaroxaban | 48 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 46 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 46 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 43 | 18 |
| Diazepam | Diazepam | 40 | suppressed |
| Meloxicam | Meloxicam | 40 | 15 |
| Tramadol Hcl | Tramadol Hcl | 39 | 17 |
| Eliquis | Apixaban | 38 | 14 |
| Spironolactone | Spironolactone | 37 | 14 |
| Estradiol | Estradiol | 33 | 12 |
| Liothyronine Sodium | Liothyronine Sodium | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | 12 |
| Alprazolam | Alprazolam | 32 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 32 | 14 |
| Ozempic | Semaglutide | 32 | 15 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 31 | 31 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 31 | 31 |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 30 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | 11 |
| Clonazepam | Clonazepam | 28 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 26 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 25 | 19 |
| Digoxin | Digoxin | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Progesterone | Progesterone, Micronized | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | 14 |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Np Thyroid | Thyroid,pork | 17 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Prednisone | Prednisone | 15 | 14 |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Forteo | Teriparatide | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Humira(Cf) Pen | Adalimumab | 12 | suppressed |
| Kesimpta Pen | Ofatumumab | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $538.23 · 19 records | ABBVIE INC. | BREZTRI, CAPLYTA, INGREZZA, OTEZLA, QULIPTA, REPATHA, SMARTVEST, UBRELVY, VRAYLAR, XYOSTED, YUPELRI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error